Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Keyphrases

• Randomized Clinical Trial 100%
• Moderate-to-severe Atopic Dermatitis 100%
• Abrocitinib 100%
• Placebo Groups 37%
• Once-daily 37%
• Placebo 25%
• Pruritus 25%
• Monotherapy 25%
• Numerical Rating Scale 25%
• Investigator's Global Assessment 25%
• Adverse Events 12%
• Placebo-controlled 12%
• South Korea 12%
• Germany 12%
• Canada 12%
• Trial Registration 12%
• United States 12%
• Selective Inhibitor 12%
• Laboratory Values 12%
• Severity Index 12%
• 4-point 12%
• Serious Adverse Events 12%
• Australia 12%
• Index Score 12%
• Japan 12%
• Clinical Diagnosis 12%
• Topical Therapy 12%
• Platelet Count 12%
• Lack of Response 12%
• Eczema 12%
• Janus Kinase 1 (JAK1) 12%
• China 12%
• Thrombocytopenia 12%
• Bulgaria 12%
• United Kingdom 12%
• Group Randomized 12%
• Poland 12%
• Area Index 12%
• Laboratory Monitoring 12%
• Latvia 12%
• Hungary 12%
• Assessment Response 12%
• Adverse Event Monitoring 12%
• Czechia 12%
• EASI Score 12%

Medicine and Dentistry

• Placebo 100%
• Randomized Clinical Trial 100%
• Atopic Dermatitis 100%
• Adverse Event 50%
• Pruritus 33%
• Adolescent 33%
• Monotherapy 33%
• Numeric Rating Scale 33%
• Platelet 16%
• Thrombocytopenia 16%
• Eczema 16%
• Topical Agent 16%
• Janus Kinase 1 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Randomized Clinical Trial 100%
• Atopic Dermatitis 100%
• Adverse Event 50%
• Pruritus 33%
• Monotherapy 33%
• Thrombocytopenia 16%
• Eczema 16%
• Topical Agent 16%
• Janus Kinase 1 16%